NovoCure (NVCR) Capital Expenditures (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.23% |
| Dec 31, 2025 | -13.42% |
| Sep 30, 2025 | 3.08% |
| Jun 30, 2025 | -48.30% |
| Mar 31, 2025 | 18.66% |
| Dec 31, 2024 | -16.30% |
| Sep 30, 2024 | -6.67% |
| Jun 30, 2024 | -2.87% |
| Mar 31, 2024 | 72.76% |
| Dec 31, 2023 | -5.96% |
| Sep 30, 2023 | 4.65% |
| Jun 30, 2023 | 13.85% |
| Mar 31, 2023 | -5.33% |
| Dec 31, 2022 | 12.77% |
| Sep 30, 2022 | 38.05% |
| Jun 30, 2022 | -18.89% |
| Mar 31, 2022 | -64.32% |
| Dec 31, 2021 | 332.94% |
| Sep 30, 2021 | 25.94% |
| Jun 30, 2021 | -34.24% |
| Mar 31, 2021 | -30.87% |
| Dec 31, 2020 | 107.01% |
| Sep 30, 2020 | -16.08% |
| Jun 30, 2020 | 6.52% |
| Mar 31, 2020 | 1.87% |
| Dec 31, 2019 | 12.81% |
| Sep 30, 2019 | 12.97% |
| Jun 30, 2019 | 3.10% |
| Mar 31, 2019 | 29.67% |
| Dec 31, 2018 | 32.52% |
| Sep 30, 2018 | 58.43% |
| Jun 30, 2018 | 15.88% |
| Mar 31, 2018 | -86.39% |
| Dec 31, 2017 | 895.40% |
| Sep 30, 2017 | 44.68% |
| Jun 30, 2017 | -63.53% |
| Mar 31, 2017 | 66.83% |
| Dec 31, 2016 | -63.97% |
| Sep 30, 2016 | -26.65% |
| Jun 30, 2016 | 133.33% |
| Mar 31, 2016 | -4.93% |
| Dec 31, 2015 | -11.87% |
| Sep 30, 2015 | -33.85% |
| Jun 30, 2015 | 196.88% |
| Mar 31, 2015 | 50.00% |